Premyelinating Oligodendrocytes in Chronic Lesions of Multiple Sclerosis
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Background Multiple sclerosis is an inflammatory disease of the central nervous system that destroys myelin, oligodendrocytes, and axons. Since most of the lesions of multiple sclerosis are not remyelinated, enhancement of remyelination is a possible therapeutic strategy that could perhaps be achieved with the transplantation of oligodendrocyte-producing cells into the lesions. We investigated the frequency distribution and configuration of oligodendrocytes in chronic lesions of multiple sclerosis to determine whether these factors limit remyelination. Methods Forty-eight chronic lesions obtained at autopsy from 10 patients with multiple sclerosis were examined immunocytochemically for oligodendrocytes and oligodendrocyte progenitor cells. Using confocal microscopy, we examined the three-dimensional relations between axons and the processes of premyelinating oligodendrocytes. Results Thirty-four of the 48 chronic lesions of multiple sclerosis contained oligodendrocytes with multiple extended processes that associated with demyelinated axons but failed to myelinate them. These axons were dystrophic and contained multiple swellings. In some regions, the densities of premyelinating oligodendrocytes (25 per square millimeter of tissue) were similar to those in the developing rodent brain (23 per square millimeter). In the patients with disease of long duration (more than 20 years), there were fewer lesions with premyelinating oligodendrocytes (P Conclusions Premyelinating oligode…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The efficacy of remyelination has been shown to depend on multiple factors such as, age, disease duration and lesion location.”
From BCAS1-positive oligodendrocytes enable efficient cortical remyelination in multiple sclerosis (2025) · cites this paper as [12]
In the citing paper
“The long‐term consequence of demyelination in the CNS is axonal damage and neurodegeneration (Chang et al. 2002) in both white and gray matter lesions, leading to progressive disease.”
From Depletion of Microglia Increases Cortical Oligodendrocyte Density During Remyelination (2026) · cites this paper as Chang et al. 2002
In the citing paper
“In MS lesions, OPCs are recruited but fail to differentiate into myelinating OLs, suggesting that remyelination is blocked at the differentiation and remyelination stage rather than during OPC recruitment (Chang et al., 2002; Kuhlmann et al., 2008; Wolswijk, 1998).”
From miR-219 Cooperates with miR-338 in Myelination and Promotes Myelin Repair in the CNS (2017) · cites this paper as Chang et al., 2002
In the citing paper
“In MS lesions, OPCs are recruited but fail to differentiate into myelinating OLs, suggesting that remyelination is blocked at the differentiation and remyelination stage rather than during OPC recruitment (Chang et al., 2002; Kuhlmann et al., 2008; Wolswijk, 1998).”
From miR-219 Cooperates with miR-338 in Myelination and Promotes Myelin Repair in the CNS (2017) · cites this paper as Chang et al., 2002
In the citing paper
“Furthermore, oligodendrocyte progenitor cells (OPCs) are a population of adult stem cells responsible for mediating CNS myelin repair in demyelinating conditions such as MS [113,114].”
From Ageing, Cellular Senescence and Neurodegenerative Disease (2018) · cites this paper as [114]
Citations
Cites
Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
Kurtzke, J. F. (1983) · Neurology · doi:10.1212/wnl.33.11.1444 · Cited by 15,011
Axonal transection in the lesions of multiple sclerosis
Trapp, B. D., Peterson, J., Ransohoff, R. M., Rudick, R., Mörk, S., & Bö, L. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801293380502 · Cited by 4,029
Self-citationNoseworthy, J. H., Lucchinetti, C., Rodriguez, M., & Weinshenker, B. G. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431307 · Cited by 2,899
Raff, M. C., Miller, R. H., & Noble, M. (1983) · Nature · doi:10.1038/303390a0 · Cited by 2,030
Axonal damage in acute multiple sclerosis lesions
Ferguson, B. (1997) · Brain · doi:10.1093/brain/120.3.393 · Cited by 1,532
WEINSHENKER, B. G., BASS, B., RICE, G. P. A., NOSEWORTHY, J., CARRIERE, W., BASKERVILLE, J., & EBERS, G. C. (1989) · Brain · doi:10.1093/brain/112.1.133 · Cited by 1,452
Cell death and control of cell survival in the oligodendrocyte lineage
Barres, B. A., Hart, I. K., Coles, H. S. R., Burne, J. F., Voyvodic, J. T., Richardson, W. D., & Raff, M. C. (1992) · Cell · doi:10.1016/0092-8674(92)90531-g · Cited by 1,345
Multiple Sclerosis and Chronic Autoimmune Encephalomyelitis
Kornek, B., Storch, M. K., Weissert, R., Wallstroem, E., Stefferl, A., Olsson, T., Linington, C., Schmidbauer, M., & Lassmann, H. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64537-3 · Cited by 921
The oligodendrocyte and its many cellular processes
PFEIFFER, S., WARRINGTON, A., & BANSAL, R. (1993) · Trends in Cell Biology · doi:10.1016/0962-8924(93)90213-k · Cited by 737
NG2-Positive Oligodendrocyte Progenitor Cells in Adult Human Brain and Multiple Sclerosis Lesions
Chang, A., Nishiyama, A., Peterson, J., Prineas, J., & Trapp, B. D. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-17-06404.2000 · Cited by 712
Self-citation
Research works printed but not linked: 2
- 10.1056/nejm199801293380610 · doi:10.1056/nejm199801293380610 · Paper page
- Prineas JW, 1989, Lab Invest, 61, 489
Cited by
Items 501–600 of 1,000
Navigating oligodendrocyte precursor cell aging in brain health
Leenders, F., Koole, L., Slaets, H., Tiane, A., van den Hove, D., & Vanmierlo, T. (2024) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2024.111959 · Cited by 35
“Additionally, there is a rise in damage to mitochondrial DNA (mtDNA) and nuclear DNA, partly attributed to increased ROS levels associated with demyelination and increased mitochondrial activity (77, 78).”
BackgroundLee, H. K., Laug, D., Zhu, W., Patel, J. M., Ung, K., Arenkiel, B. R., Fancy, S. P. J., Mohila, C., & Deneen, B. (2015) · Glia · doi:10.1002/glia.22848 · Cited by 33
“In these conditions, the ability of oligodendrocyte precursors (OLPs) to remyelinate white matter lesions is often impaired, as “stalled” OLP populations are found within sites of WMI in humans (Chang et al., 2000; Emery, 2010; Franklin, 2002; Kuhlmann et al., 2008).”
BackgroundHeterogeneous populations of neural stem cells contribute to myelin repair
Küry, P., Akkermann, R., & Beyer, F. (2017) · Neural Regeneration Research · doi:10.4103/1673-5374.204999 · Cited by 30
“…that OPCs can be readily found in and around MS lesions, but are unable to differentiate into remyelinating OLs, likely due to the presence of inhibitory molecules (Scolding et al., 1998; Wolswijk, 1998; Chang et al., 2000, 2002; Kuhlmann et al., 2008; Rivera et al., 2010; Kremer et al., 2011).”
BackgroundLlufriu-Dabén, G., Carreté, A., Chierto, E., Mailleux, J., Camand, E., Simon, A., Vanmierlo, T., Rose, C., Allinquant, B., Hendriks, J. J. A., et al. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2017.09.008 · Cited by 31
“Oligodendrocyte precursor cells (OPCs), the main source of mature myelinating cells in the adult brain are not considered to be a limiting factor for remyelination since they are abundant within demyelinated regions (Chang et al., 2002).”
BackgroundDonkels, C., Peters, M., Núñez, M. T. F., Nakagawa, J. M., Kirsch, M., Vlachos, A., Scheiwe, C. F., Schulze‐Bonhage, A., Prinz, M., Beck, J., et al. (2019) · Epilepsia · doi:10.1111/epi.16415 · Cited by 31
Modulation of lanosterol synthase drives 24,25-epoxysterol synthesis and oligodendrocyte formation
Hubler, Z. M. L., Friedrich, R. M., Sax, J. L., Allimuthu, D., Gao, F., Rivera-León, A. M., Pleshinger, M. J. A., Bederman, I. R., & Adams, D. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2021.01.025 · Cited by 32
Wilczak, N., Chesik, D., Hoekstra, D., & Keyser, J. D. (2008) · Neurochemistry International · doi:10.1016/j.neuint.2008.03.004 · Cited by 30
“Most chronic lesions of MS are not remyelinated, although oligodendrocyte precursors and premyelinating oligodendrocytes are present in periplaque white matter (Chang et al., 2000, 2002; Lucchinetti et al., 1999; Ozawa et al., 1994; Scolding et al., 1998; Wolswijk, 2000, 2002).”
Kamali‐Sarvestani, E., Nikseresht, A., Aliparasti, M.-R., & Vessal, M. (2006) · Neuroscience Letters · doi:10.1016/j.neulet.2006.05.033 · Cited by 30
Choi, E. H., Xu, Y., Medynets, M., Monaco, M. C., Major, E. O., Nath, A., & Wang, T. (2018) · Glia · doi:10.1002/glia.23501 · Cited by 31
Prozorovski, T., Ingwersen, J., Lukas, D., Göttle, P., Koop, B. E., Graf, J., Schneider, R., Franke, K., Schumacher, S., Britsch, S., et al. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2019.04.007 · Cited by 30
Multiple paradigm shifts in multiple sclerosis
Kieseier, B. C., & Hartung, H. (2003) · Current Opinion in Neurology · doi:10.1097/00019052-200306000-00001 · Cited by 31
Sullivan, G. M., Knutsen, A. K., Peruzzotti-Jametti, L., Korotcov, A., Bosomtwi, A., Dardzinski, B. J., Bernstock, J. D., Rizzi, S., Edenhofer, F., Pluchino, S., et al. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-00960-3 · Cited by 29
Karadimas, S. K., Gialeli, C., Klironomos, G., Tzanakakis, G. N., Panagiotopoulos, E. C., Karamanos, N. K., & Gatzounis, G. D. (2010) · Current Medicinal Chemistry · doi:10.2174/092986710790820598 · Cited by 32
Protandim Protects Oligodendrocytes against an Oxidative Insult
Lim, J. L., van der Pol, S. M. A., Baron, W., McCord, J. M., de Vries, H. E., & van Horssen, J. (2016) · Antioxidants · doi:10.3390/antiox5030030 · Cited by 30
“As oligodendrocyte progenitor cells (OPCs) were detected in chronic lesions [5,6], it appears that premyelinating OLs fail to differentiate and ensheath the axon with myelin in chronic MS.”
BackgroundEmerging role of semaphorin-3A in autoimmune diseases
Liu, L., Li, X., Ye, D., & Pan, H. (2018) · Inflammopharmacology · doi:10.1007/s10787-018-0484-y · Cited by 30
“Due to immune attack, the myelin sheath can be exfoliated, which slows nerve conduction and leads to neurological symptoms (Chang et al. 2002; Huseby et al. 2001).”
BackgroundMyelin is repaired by constitutive differentiation of oligodendrocyte progenitors
Mironova, Y. A., Dang, B., Heo, D., Xu, Y. K. T., Hsu, A. T.-W., von Bernhardi, J. E., Molina-Castro, G. C., Kim, A. A., LIN, J., Reich, D. S., et al. (2026) · Science · doi:10.1126/science.adu2896 · Cited by 30
Limited TCF7L2 Expression in MS Lesions
Lürbke, A., Hagemeier, K., Cui, Q.-L., Metz, I., Brück, W., Antel, J., & Kuhlmann, T. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072822 · Cited by 28
“oligodendrocytes contributes to remyelination failure [15–17].”
Yoga as an intervention to manage multiple sclerosis symptoms
Thakur, P., Mohammad, A., Rastogi, Y. R., Saini, R. V., & Saini, A. K. (2019) · Journal of Ayurveda and Integrative Medicine · doi:10.1016/j.jaim.2019.04.005 · Cited by 30
Sosa, R. A., & Forsthuber, T. G. (2011) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2011.0052 · Cited by 33
Axonal degeneration stimulates the formation of NG2+ cells and oligodendrocytes in the mouse
Nielsen, H. H., Ladeby, R., Drøjdahl, N., Peterson, A. C., & Finsen, B. (2006) · Glia · doi:10.1002/glia.20357 · Cited by 28
“godendrocytes and delayed axonal damage (Chang et al., 2002; Kuhlmann et al., 2002; Trapp et al., 1998).”
Ramasamy, D. P., Ramanathan, M. K., Cox, J. L., Antulov, R., Weinstock‐Guttman, B., Bergsland, N., Benedict, R. H. B., Dwyer, M. G., Minagar, A., & Zivadinov, R. (2010) · Pathophysiology · doi:10.1016/j.pathophys.2010.04.006 · Cited by 33
“Possible mechanisms for repair failure nclude reduced differentiation or recruitment of oligodenrocytes as a consequence of immune cell attack [5], an mbalance of growth factors [6], or the release by immune ells of molecules/signals that inhibit remyelination [7].”
BackgroundMarkovic‐Plese, S., Singh, A. K., & Singh, I. (2008) · Future Neurology · doi:10.2217/14796708.3.2.153 · Cited by 29
“7) [60–62].”
BackgroundCXCR7 Is Involved in Human Oligodendroglial Precursor Cell Maturation
Kremer, D., Cui, Q., Göttle, P., Kuhlmann, T., Hartung, H., Antel, J. P., & Küry, P. (2016) · PLoS ONE · doi:10.1371/journal.pone.0146503 · Cited by 28
“Inefficient CNS remyelination observed in neuroinflammatory demyelinating diseases such as MS is tightly linked to the limited ability of resident OPCs to differentiate properly—a prerequisite for subsequent remyelination [5, 28].”
BackgroundMagalon, K., Grand, M. L., Waly, B. E., Moulis, M., Pruss, R. M., Bordet, T., Cayre, M., Belenguer, P., Carré, M., & Durbec, P. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.09.009 · Cited by 28
Tomassy, G. S., & Fossati, V. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00201 · Cited by 29
Mechanisms of oligodendrocyte progenitor developmental migration
Xia, W., & Fancy, S. P. J. (2021) · Developmental Neurobiology · doi:10.1002/dneu.22856 · Cited by 29
“But OPCs are often limited in numbers in chronic lesions, do not appear to migrate a great distance into the lesions, and occupy a small proportion of the total lesion area (Chang et al., 2002).”
BackgroundSmith, B. C., Tinkey, R. A., Brock, O. D., Mariam, A., Habean, M. L., Dutta, R., & Williams, J. L. (2023) · Journal of Neuroinflammation · doi:10.1186/s12974-023-02917-4 · Cited by 28
So many progenitors, so little myelin
Goldman, S. A., & Osório, M. J. (2014) · Nature Neuroscience · doi:10.1038/nn.3685 · Cited by 27
Imbschweiler, I., Seehusen, F., Peck, C., Omar, M., Baumgärtner, W., & Wewetzer, K. (2011) · Glia · doi:10.1002/glia.22270 · Cited by 28
“…the emergence of premyelinating oligodendrocytes or CNS Schwann-like glia has been discussed mainly in the context of demyelination so far (Chang et al., 2002; Di Bello et al., 1999; Talbott et al., 2006), the fact that a multitude of diverse experimental paradigms resulted in formation…”
BackgroundImaging Axonal Degeneration and Repair in Preclinical Animal Models of Multiple Sclerosis
Yandamuri, S. S., & Lane, T. E. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00189 · Cited by 27
“It is believed that remyelination, reduced neuroinflammation, and adaptive CNS responses are responsible for remitting phases of disease (7) (8) (9) (10) .”
BackgroundExpression of Bone Morphogenetic Proteins in Multiple Sclerosis Lesions
Costa, C., Eixarch, H., Martínez-Sáez, E. A., Calvo‐Barreiro, L., Calucho, M., Castro, Z., Aznar, A. O., y Cajal, S. R., Montalbán, X., & Espejo, C. (2018) · American Journal Of Pathology · doi:10.1016/j.ajpath.2018.11.007 · Cited by 27
Chesik, D., Keyser, J. D., Bron, R., & Fuhler, G. M. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06703.x · Cited by 27
“The formation of new myelin sheaths in MS, remyelination, is a regenerative process involving restoration of pre-lesion cytoarchitecture (Chang et al. 2002).”
BackgroundHuman Monoclonal IgM Antibody Promotes CNS Myelin Repair Independent of Fc Function
Ćirić, B., Howe, C. L., Soldán, M. M. P., Warrington, A. E., Bieber, A. J., Keulen, V. P. V., Rodriguez, M., & Pease, L. R. (2003) · Brain Pathology · doi:10.1111/j.1750-3639.2003.tb00489.x · Cited by 27
“However, in the majority of MS cases remyelination is incomplete, even though the glial cell progenitors often are preserved in the lesion (7).”
BackgroundArmstrong, R. C. (2007) · Future Neurology · doi:10.2217/14796708.2.6.689 · Cited by 27
Non-specific immunosuppressants in the treatment of multiple sclerosis
Confavreux, C., & Vukusic, S. (2004) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2004.02.012 · Cited by 31
“In this respect, some advances have already been made: premyelinating oligodendrocytes are present in MS plaques [38]; but, while capable of remyelination, they remain quiescent, and it is critical that means for making them actively remyelinate be found.”
BackgroundRemyelination strategies in multiple sclerosis: a critical reflection
Kipp, M. (2015) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2016.1116387 · Cited by 28
“[2] Although it is principally possible that remyelination fails because the repair process per se is too slow and accelerating this process might well be beneficial for neuronal health, I consider it more likely that the environment is not supportive for myelin repair which could, among other mechanisms, impair OPC d…”
BackgroundAnti lingo 1 (opicinumab) a new monoclonal antibody tested in relapsing remitting multiple sclerosis
Ruggieri, S., Tortorella, C., & Gasperini, C. (2017) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2017.1378098 · Cited by 28
Myelin-based inhibitors of oligodendrocyte myelination: clues from axonal growth and regeneration
Mei, F., Chong, S. Y. C., & Chan, J. R. (2013) · Neuroscience Bulletin · doi:10.1007/s12264-013-1319-x · Cited by 26
“[19] Chang A, Tourtellotte WW, Rudick R, Trapp BD.”
Background4 Tubulin Identifies a Primitive Cell Source for Oligodendrocytes in the Mammalian Brain
Wu, C., Chang, A., Smith, M. C., Won, R., Yin, X., Staugaitis, S. M., Agamanolis, D. P., Kidd, G. J., Miller, R. H., & Trapp, B. D. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.1027-09.2009 · Cited by 29
“MS brains were obtained from prospectively consented donors and characterized as described previously (Trapp et al., 1997, 1998; Chang et al., 2002).”
BackgroundMethodInfluentialSelf-citationIn vivo insulin deficiency as a potential etiology for demyelinating disease
Gong, X., Xie, Z., & Zuo, H. (2008) · Medical Hypotheses · doi:10.1016/j.mehy.2008.04.006 · Cited by 27
Azin, M., Mirnajafi‐Zadeh, J., & Javan, M. (2015) · PubMed Central · doi:10.22074/cellj.2015.14 · Cited by 26
“Based on a previous report, treatment with FGF2 in animals suffering from experimental autoimmune encephalomyelitis (EAE) reduced the extent of demyelination (23).”
BackgroundMultiple Sclerosis: Basic and Clinical
Buzzard, K. A., Chan, W. H., Kilpatrick, T. J., & Murray, S. S. (2017) · Advances in neurobiology · doi:10.1007/978-3-319-57193-5_8 · Cited by 36
Cole, A., Wood, R. J., Fletcher, J. L., Gonsalvez, D. G., Merlo, D., Cate, H. S., Murray, S. S., & Xiao, J. (2019) · eNeuro · doi:10.1523/eneuro.0399-18.2019 · Cited by 27
“…chronically demyelinated lesions typically contain oligodendrocyte progenitor cells (OPCs) and premyelinating OLs that have “stalled” in their differentiation, implicating blocked OL differentiation as a major contributing factor to remyelination failure (Chang et al., 2002; Kuhlmann et al., 2008).”
BackgroundKapoor, T., & Mehan, S. (2020) · Current Drug Discovery Technologies · doi:10.2174/1570163817666200207100903 · Cited by 26
Stem cell therapies for perinatal brain injuries
Vawda, R., Woodbury, J., Covey, M. V., Levison, S. W., & Mehmet, H. (2007) · Seminars in Fetal and Neonatal Medicine · doi:10.1016/j.siny.2007.02.003 · Cited by 27
Pinocembrin Promotes OPC Differentiation and Remyelination via the mTOR Signaling Pathway
Shao, Q., Zhao, M., Pei, W., Pu, Y., Liu, M., Liu, W., Yu, Z., Chen, K., Liu, H., Deng, B., et al. (2021) · Neuroscience Bulletin · doi:10.1007/s12264-021-00696-7 · Cited by 26
Koehler, N. K. U., Roebbert, M., Dehghani, K., Ballmaier, M., Claus, P., von Hörsten, S., Shing, M., Odin, P., Strehlau, J., & Heidenreich, F. (2007) · Journal of Neuroscience Research · doi:10.1002/jnr.21497 · Cited by 25
“Importantly, O2A cells are abundant in CNS lesions of MS patients (Chang et al., 2000, 2002; Maeda et al., 2001; Chari and Blakemore, 2002), with PDGF and FGF-2 being possibly the predominant factors in regulating the O2A responses to demyelination (Frost et al., 2003).”
BackgroundResultScalabrino, G., Veber, D., Giuseppe, R. D., & Roncaroli, F. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.04.020 · Cited by 26
“…results support the ‘‘dysregulation hypothesis’’ according to which inappropriately regulated or dysregulated CNS factors are responsible for remyelination failure in MS (Chang et al., 2002; Franklin, 2002; Lisak, 2007; Franklin and ffrench-Constant, 2008; Patel and Klein, 2011; Bø et al., 2013).”
InfluentialLu, F., Yin, D., Pu, Y., Liu, W., Li, Z., Shao, Q., He, C., & Cao, L. (2019) · Neuroscience Bulletin · doi:10.1007/s12264-018-0322-7 · Cited by 27
Thümmler, K., Rom, E., Zeis, T., Lindner, M., Brunner, S. P., Cole, J. J., Arseni, D., Mücklisch, S., Edgar, J. M., Schaeren‐Wiemers, N., et al. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0864-6 · Cited by 25
Yamasaki, R., & Kira, J. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-32-9636-7_14 · Cited by 29
Edgar, J. M., & Griffiths, I. R. (2009) · Elsevier eBooks · doi:10.1016/b978-0-12-374709-9.00005-5 · Cited by 29
Lassmann, H. (2005) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2005.03.007 · Cited by 25
“Thus, there are cells present, which in principal have the capacity to remyelinate, but they do not accomplish this task [25].”
BackgroundThe Yin and Yang of cell cycle progression and differentiation in the oligodendroglial lineage
Nguyen, L., Borgs, L., Vandenbosch, R., Mangin, J., Beukelaers, P., Moonen, G., Gallo, V., Malgrange, B., & Belachew, S. M. (2006) · Mental Retardation and Developmental Disabilities Research Reviews · doi:10.1002/mrdd.20103 · Cited by 28
Pérez-Bouza, A., Glaser, T., & Brüstle, O. (2005) · Brain Pathology · doi:10.1111/j.1750-3639.2005.tb00522.x · Cited by 28
“208 Myelinating ES Cell Transplants—Perez-Bouza et al INTRODUCTION In human inflammatory demyelinating diseases such as multiple sclerosis (MS), spontaneous myelin repair by endogenous oligodendroglia occurs but is limited in its extent (7, 31, 32, 43).”
BackgroundOkuda, D. T., Moog, T. M., McCreary, M., Bachand, J. N., Wilson, A., Wright, K., Winkler, M. D., Ramos, O. G., Blinn, A. P., Wang, Y., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-76420-8 · Cited by 24
Lohrberg, M., Winkler, A., Franz, J., van der Meer, F., Ruhwedel, T., Sirmpilatze, N., Dadarwal, R., Löber-Handwerker, R., Esser, D. S., Wiegand, K., et al. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-01105-2 · Cited by 26
“experimental ODS lesions, but are mainly BrdU negative The proper differentiation of OPCs into myelinating oligodendrocytes has been identified as a limiting factor for efficient remyelination in MS [16, 58].”
BackgroundSchmidt, F., van den Eijnden, M., Gobert, R. P., Saborío, G. P., Carboni, S., Alliod, C., Pouly, S., Staugaitis, S. M., Dutta, R., Trapp, B. D., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040457 · Cited by 25
“SP-MS lesions often demonstrate a lack of remyelination, despite the recruitment of oligodendrocyte precursor cells (OPCs) in the peri-lesional area, as observed in post-mortem analyses [1,2].”
BackgroundSelf-citationAccelerated repair of demyelinated CNS lesions in the absence of non‐muscle myosin IIB
Rusielewicz, T., Nam, J., Damanakis, E., John, G. R., Raine, C. S., & Melendez‐Vasquez, C. V. (2014) · Glia · doi:10.1002/glia.22627 · Cited by 26
“1D) cell with a morphology consistent with that of non-myelinating pre-oligodendrocytes (Chang et al., 2002).”
Extracellular Acidic pH Inhibits Oligodendrocyte Precursor Viability, Migration, and Differentiation
Jagielska, A., Wilhite, K. D., & Vliet, K. J. V. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076048 · Cited by 26
“During initial stages of MS, OPCs typically rapidly respond to myelin loss with increased proliferation and migration toward the lesion, often followed by relatively efficient differentiation and remyelination [13,18,75,145,146].”
BackgroundAn unmet clinical need: roads to remyelination in MS
Göttle, P., Förster, M., Weyers, V., Küry, P., Rejdak, K., Hartung, H., & Kremer, D. (2019) · Neurological Research and Practice · doi:10.1186/s42466-019-0026-0 · Cited by 24
“Even though there is evidence that adult oligodendrocyte can contribute to myelin repair in the adult CNS [18, 103], remyelination is thought to be mostly mediated by an ubiquitous pool of so-called oligodendroglial precursor cells (OPCs) which can differentiate into mature cells and then generate new myelin [10].”
BackgroundFranco‐Pons, N., Tomàs-Roig, J., Roig, B., Auladell, C., Martorell, L., & Vilella, E. (2008) · Journal of Molecular Neuroscience · doi:10.1007/s12031-008-9151-x · Cited by 27
“Remyelination occurs when the CNS attempts to recover from myelin loss (Chang et al. 2002).”
Cellular Damage and Repair in Multiple Sclerosis
Lassmann, H. (2004) · Elsevier eBooks · doi:10.1016/b978-012439510-7/50084-x · Cited by 28
The Roles of hnRNP Family in the Brain and Brain-Related Disorders
Brandão‐Teles, C., Antunes, A. S. L. M., Vrechi, T. A. D. M., & Martins‐de‐Souza, D. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03747-4 · Cited by 26
Lisak, R. P., Nedelkoska, L., & Benjamins, J. A. (2014) · Glia · doi:10.1002/glia.22639 · Cited by 23
“It would also be important to protect OPC since these cells are likely the source of remyelination (Chang et al., 2002; Lassmann et al., 1997; Lucchinetti et al., 1999; Patrikios et al., 2006) so as to optimize remyelination following damage in MS.”
BackgroundPolydendrocytes in development and myelin repair
Zuo, H., & Nishiyama, A. (2013) · Neuroscience Bulletin · doi:10.1007/s12264-013-1320-4 · Cited by 28
“dendrocytes is the critical stage for remyelination of demyelinated axons([111]), the lack of oligodendrocytes is still con-”
Multiple Sclerosis Therapies: Molecular Mechanisms and Future
da Fontoura, P. P., & Garren, H. (2009) · Results and problems in cell differentiation · doi:10.1007/400_2010_36 · Cited by 25
“Remyelination has been shown to occur in a significant percentage of MS lesions, and the presence of oligodendrocyte progenitors has been well documented ( Chang et al. 2002; Patrikios et al. 2006).”
BackgroundCurrent status of myelin replacement therapies in multiple sclerosis
Huang, J. K., & Franklin, R. J. M. (2012) · Progress in brain research · doi:10.1016/b978-0-444-59544-7.00011-1 · Cited by 23
FSD-C10, a Fasudil derivative, promotes neuroregeneration through indirect and direct mechanisms
Lǐ, Y., Xie, C., Zhang, Y., Li, X., Zhang, H., Wang, Q., Chai, Z., Xiao, B., Thomé, R., Zhang, G., et al. (2017) · Scientific Reports · doi:10.1038/srep41227 · Cited by 24
Li, T., Wang, L., Ma, T., Wang, S., Niu, J., Li, H., & Xiao, L. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00162 · Cited by 24
“…in Molecular Neuroscience | www.frontiersin.org 1 May 2018 | Volume 11 | Article 162 demyelination diseases such as multiple sclerosis (MS; Wolswijk, 1998; Chang et al., 2002; Kuhlmann et al., 2008), promoting OPC differentiation into mature OLs becomes a promising approach for myelin repair.”
BackgroundWerkman, I. L., Dubbelaar, M. L., van der Vlies, P., de Boer-Bergsma, J. J., Eggen, B. J. L., & Baron, W. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-02045-3 · Cited by 21
“Also, in the chronic demyelinating disease multiple sclerosis (MS), remyelination is more efficient in GM than in WM [40, 41], but ultimately fails in both areas, contributing to disease progression [1, 42, 43].”
BackgroundLi, Q., Ru, X., Yang, Y., Zhao, H., Qu, J., Chen, W., Pan, P., Ruan, H., Li, C., Chen, Y., et al. (2022) · Neuroscience Bulletin · doi:10.1007/s12264-022-00906-w · Cited by 23
“However, the understanding of the efficiency of oligodendrogenesis and remyelination in the adult CNS is limited [45] for two complementary reasons.”
BackgroundEmerging Therapies for Multiple Sclerosis
Muraro, P. A., & Bielekova, B. (2007) · Neurotherapeutics · doi:10.1016/j.nurt.2007.07.003 · Cited by 23
“The use of sHIgM22 in a proof-of-principle clinical trial will be extremely important to determine if demyelination associated with MS is unique in comparison to animal models of CNS demyelination, and whether sHIgM22 is capable of overcoming an apparent block in effective remyelination that has been postulated in MS.…”
Remyelination modulators in multiple sclerosis patients
Al-Temaimi, R. A., Abubaker, J. A., Al‐Khairi, I., & Alroughani, R. (2017) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2017.11.004 · Cited by 24
Re-Expression of a Developmentally Restricted Potassium Channel in Autoimmune Demyelination
Herrero-Herranz, E., Pardo, L. A., Bunt, G., Gold, R., Stühmer, W., & Linker, R. A. (2007) · American Journal Of Pathology · doi:10.2353/ajpath.2007.061241 · Cited by 27
Remyelinating and neuroprotective treatments in multiple sclerosis
Stangel, M. (2004) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.13.4.331 · Cited by 22
Imamura, O., Arai, M., Dateki, M., & Takishima, K. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13856 · Cited by 23
Skaper, S. D., Barbierato, M., Facci, L., Borri, M., Contarini, G., Zusso, M., & Giusti, P. (2017) · Molecular Neurobiology · doi:10.1007/s12035-017-0722-0 · Cited by 22
“Apart from white matter and gray matter lesions in the CNS [3–5], a distinguishing feature of MS lesions is the presence of undifferentiated oligodendrocyte progenitor cells (OPCs) [6], a likely consequence of their inability to progress to a myelinproducing phenotype.”
Lopez-Caraballo, L., Martorell‐Marugán, J., Carmona‐Sáez, P., & González-Muñoz, E. (2020) · Cells · doi:10.3390/cells9081803 · Cited by 23
“Studies have revealed the presence of undifferentiated OPCs in progressive MS lesions [29,53].”
BackgroundRole of Mayven, a kelch‐related protein in oligodendrocyte process formation
Williams, S. K., Spence, H. J., Rodgers, R. R., Ozanne, B. W., FitzGerald, U., & Barnett, S. C. (2005) · Journal of Neuroscience Research · doi:10.1002/jnr.20588 · Cited by 23
“Recently, it has been shown that there are mature oligodendrocytes lacking processes present in chronic MS lesions, which have survived the loss of their myelin sheaths (Wolswijk, 2000) but failed to wrap myelin around the axon (Chang et al., 2002).”
BackgroundTeske, N., Liessem-Schmitz, A., Fischbach, F., Clarner, T., Beyer, C., Wruck, C. J., Fragoulis, A., Tauber, S. C., Victor, M. B., & Kipp, M. (2018) · Journal of Neurochemistry · doi:10.1111/jnc.14270 · Cited by 23
“…impairment of both, OPC recruitment and differentiation, might be attributable to the failure of remyelination in MS patients and its animal models (Chang et al. 2000, 2002; Sim et al. 2002), OPC death during the remyelination process has been suggested to contribute to remyelination failure…”
BackgroundSobel, R. A., & Moore, G. W. (2008) · CRC Press eBooks · doi:10.1201/b13319-21 · Cited by 35
Remyelination in animal models of multiple sclerosis: finding the elusive grail of regeneration
Packer, D., Fresenko, E. E., & Harrington, E. P. (2023) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2023.1207007 · Cited by 21
“, 2008), and impaired contact of differentiated oligodendrocytes with demyelinated axons (Chang et al., 2002).”
BackgroundLi, W., Berlinicke, C. A., Huang, Y., Giera, S., McGrath, A. G., Fang, W., Chen, C., Takaesu, F., Chang, X., Duan, Y., et al. (2023) · iScience · doi:10.1016/j.isci.2023.106156 · Cited by 26
What Are the Roles of Oligodendrocyte Precursor Cells in Normal and Pathologic Conditions?
Benarroch, E. E. (2023) · Neurology · doi:10.1212/wnl.0000000000208000 · Cited by 24
Zhou, L., Shao, C., Xu, S., Ma, J., Xie, Y., Zhou, L., Teng, P., Wang, Y., Qiu, M. S., & Shen, Y. (2014) · Molecular Neurobiology · doi:10.1007/s12035-014-8678-9 · Cited by 23
Dittmer, M., Young, A., O’Hagan, T., Eleftheriadis, G., Bankhead, P., Dombrowski, Y., Medina, R. J., & Fitzgerald, D. C. (2018) · Molecular Brain · doi:10.1186/s13041-018-0367-6 · Cited by 23
“Therefore, a key bottle-neck in remyelination appears to be oligodendrocyte differentiation and subsequent remyelination [3, 6, 7].”
BackgroundProtein Tyrosine Phosphatase Receptor Type Z in Central Nervous System Disease
Nagai, K., Fujii, M., & Kitazume, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084414 · Cited by 25
Loss of epidermal growth factor regulation by cobalamin in multiple sclerosis
Scalabrino, G., Galimberti, D., Mutti, E., Scalabrini, D., Veber, D., Riz, M. A. D., Bamonti, F., Capello, E., Mancardi, G., & Scarpini, E. A. (2010) · Brain Research · doi:10.1016/j.brainres.2010.03.073 · Cited by 26
Fc Receptor-Positive Cells in Remyelinating Multiple Sclerosis Lesions
Nakahara, J., & Aiso, S. (2006) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-200606000-00006 · Cited by 23
“In contrast to the old view thatMS lesions are deprived of oligodendrocytes and that the insufficient remyelination activity is the result of the lack of myelinating cells, recent evidence has shown that oligodendrocyte precursor cells and immature oligodendrocytes (OPC/iOligs) are preserved in the lesions (8, 9).”
MethodResultPromoting myelin repair and return of function in multiple sclerosis
Zhang, J., Kramer, E. G., Asp, L., Dutta, D. J., Navrazhina, K., Pham, T., Mariani, J. N., Argaw, A. T., Melendez‐Vasquez, C. V., & John, G. R. (2011) · FEBS Letters · doi:10.1016/j.febslet.2011.08.017 · Cited by 23
Staugaitis, S. M., Chang, A., & Trapp, B. D. (2012) · Acta Neurologica Scandinavica · doi:10.1111/ane.12041 · Cited by 23
“Premyelinating oligodendrocytes may be present in either white-matter (18) or cortical lesions (10; Fig 3A), but they are rare.”
BackgroundSelf-citationTargeting Oligodendrocyte Protection and Remyelination in Multiple Sclerosis
Zhang, J., Kramer, E. G., Mahase, S. S., Dutta, D. J., Bonnamain, V., Argaw, A. T., & John, G. R. (2011) · Mount Sinai Journal of Medicine A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20244 · Cited by 24
“Although myelin repair has been demonstrated in early lesions in MS, and is associated with recovery of conduction and return of function [3,4], remyelination is known to gradually fail with disease progression [5,6].”
BackgroundMausner-Fainberg, K., Urshansky, N., Regev, K., Auriel, E., & Karni, A. (2013) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2013.09.004 · Cited by 21
“Indeed, enhanced levels of precursor cells of neurons (NPCs) and of oligodendrocytes (OPCs) derived from the neuroproliferative niches have been observed in MS lesions (Wolswijk, 1998; Chang et al., 2002; Snethen et al., 2008) aswell as in amurinemodel of experimental autoimmune encephalomyelitis (EAE) (Picard-Riera e…”
BackgroundProgesterone effects on oligodendrocyte differentiation in injured spinal cord
Jure, I., Nicola, A. F. D., & Labombarda, F. (2018) · Brain Research · doi:10.1016/j.brainres.2018.12.005 · Cited by 22
Stem Cell and Gene-Based Therapy
Battler, A., & Leor, J. (2006) · Springer eBooks · doi:10.1007/1-84628-142-3 · Cited by 27
Ohta, K., Iwai, M., Sato, K., Omori, N., Nagano, I., Shoji, M., & Abe, K. (2003) · Neuroscience Letters · doi:10.1016/s0304-3940(02)01177-1 · Cited by 20
Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
Dutta, R., Mahajan, K. R., Nakamura, K., Ontaneda, D., Chen, J. M., Volsko, C. M., Dudman, J., Christie, E., Dunham, J., Fox, R. J., et al. (2019) · Journal of Visualized Experiments · doi:10.3791/59511 · Cited by 22
Self-citationS100B Impairs Oligodendrogenesis and Myelin Repair Following Demyelination Through RAGE Engagement
Santos, G., Barateiro, A. P., Brites, D. M. T. O., & Fernandes, A. M. A. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00279 · Cited by 21
Cid, C., Alvarez-Cermeño, J. C., Salinas, M., & Alcázar, A. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03371.x · Cited by 21
Metadata
- Authors
- Chang, A., Tourtellotte, W. W., Rudick, R., & Trapp, B. D.
- Affiliations
- Cleveland Clinic (US)
- VA West Los Angeles Medical Center (US)
- Cleveland Clinic Research (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2002-01-17
- Volume
- 346
- Issue
- 3
- Pages
- 165-173
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2058358434
- Cited by
- 991
- References
- 39
- Citations by year
- 2026: 19 · 2025: 25 · 2024: 42 · 2023: 38 · 2022: 32 · 2021: 34 · 2020: 36 · 2019: 57 · 2018: 43 · 2017: 52 · 2016: 44 · 2015: 55 · 2014: 44 · 2013: 50 · 2012: 40
- FWCI
- 26.66
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Neurological Disorders and Stroke (R01 NS35058, P01NS038667, R01NS035058, P01-NS-38667)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Life Sciences › Neuroscience › Developmental Neuroscience › Neurogenesis and neuroplasticity mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
- Keywords
- multiple sclerosis, remyelination, chronic lesions, demyelinated axons, oligodendrocyte precursor cells, disease duration
- MeSH terms
- Chondroitin Sulfate Proteoglycan 4, Adult, Aged, Antigens, Axons, Brain, Brain Chemistry, Female, Humans, Male, Middle Aged, Multiple Sclerosis, Nerve Fibers, Myelinated, Oligodendroglia, Proteoglycans, Stem Cells, Microscopy, Confocal
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.